Recommended immunization schedules: Canadian Immunization Guide

For health professionals

Notice

This chapter has not yet been updated with the following guidance from the National Advisory Committee on Immunization (NACI):
- May 14, 2025: Updated recommendations on Herpes Zoster vaccination for adults who are immunocompromised
- November 15, 2024: Summary of statement on recommendations on the use of pneumococcal vaccines in adults, including PNEU-C-21
This CIG chapter has not been updated to contain any information regarding COVID-19 vaccines, refer to the COVID-19 vaccines chapter.

Last partial content update : April 2025

This chapter has been updated with guidance from the following statements from the National Advisory Committee on Immunization (NACI):

This information is captured in the table of updates.

Last complete chapter revision: December 2013

General recommendations
Table 1: Routine childhood immunization schedule, infants and children (birth to 17 years of age)
Table 2: Recommended immunization schedule, children (less than 7 years of age), NOT previously immunized as infants
Table 3: Recommended immunization schedule, children (7 to 17 years of age), NOT previously immunized
Table 4: Additional recommended immunizations, children (birth to 17 years of age), considered at risk due to underlying medical conditions
Table 5: Recommended immunization schedule, adults (18 years of age and older), NOT previously immunized
Table 6: Recommended immunizations, adults (18 years of age and older), previously immunized
Table 7: Additional recommended immunizations, adults (18 years of age and older), considered at risk

General recommendations

Administration of vaccines in accordance with the immunization schedules summarized in the following tables will provide optimal protection from vaccine preventable diseases for most individuals. However, modifications of the recommended schedule may be necessary due to missed appointments or illness. In general, interruption of an immunization series does not require restarting the vaccine series, regardless of the interval between doses. Individuals with interrupted immunization schedules should be vaccinated to complete the appropriate schedule for their current age. Refer to Timing of vaccine administration in Part 1 and vaccine-specific chapters in Part 4 for additional information.

Similar, but not identical, vaccines may be available from different manufacturers; therefore, it is useful to review the relevant vaccine-specific chapters in the Canadian Immunization Guide as well as the manufacturer's product leaflet or product monograph before administering a vaccine. Refer to Principles of vaccine interchangeability in Part 1 for information about the interchangeability of similar vaccines from different manufacturers. Product monographs are periodically updated; it is a best practice to consult the information contained within the product monographs available through Health Canada's Drug Product Database.

Table 1: Routine childhood immunization schedule, infants and children (birth to 17 years of age)

For children at-risk due to underlying medical conditions, refer to Table 4 for additional recommendations for immunization.
[ ] = dose(s) may not be required depending upon age of child or vaccine used or both (refer to the relevant vaccine-specific chapter in Part 4 and provincial/territorial schedule). mos = months. yrs = years. P/T = provincial and territorial.
Refer to Timing of vaccine administration and Vaccine administration practices in Part 1 regarding administration of multiple injections.
Refer to vaccine-specific chapters in Part 4 for additional information.

Table 1: Routine childhood immunization schedule, infants and children (birth to 17 years of age
Immunizing Agent^{Table 1 Footnote *}	Age
Immunizing Agent^{Table 1 Footnote *}	Birth	2 mos	4 mos	6 mos	12 mos	15 mos	18 mos	23 mos	2 years	4 years	5 years	6 years	9 years	12 years	14 years	15 years	16 years	17 years
DTaP-IPV-Hib or DTaP-HB-IPV-Hib	-	DTaP-IPV-Hib ^{Table 1 Footnote A} or DTaP-HB-IPV-Hib ^{Table 1 Footnote B} 1st dose	DTaP-IPV-Hib ^{Table 1 Footnote A} or DTaP-HB-IPV-Hib ^{Table 1 Footnote B} 2nd dose	DTaP-IPV-Hib ^{Table 1 Footnote A} or DTaP-HB-IPV-Hib ^{Table 1 Footnote B} 3rd dose	DTaP-IPV-Hib ^{Table 1 Footnote A} or 4th dose Generally at 18 months of age				-	-	-	-	-	-	-	-	-	-
DTaP-IPV or Tdap-IPV	-	-	-	-	-	-	-	-	-	DTaP-IPV or Tdap-IPV			-	-	-	-	-	-
Tdap	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Tdap ^{Table 1 Footnote C}			-
Rot	-	2 or 3 doses Complete series before 8 months ^{Table 1 Footnote D}			-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pneu-C-15 or Pneu-C-20	-	Pneu-C-15 or Pneu-C-20^{Table 1 Footnote E}			Pneu-C-15 or Pneu-C-20^{Table 1 Footnote E}		-	-	-	-	-	-	-	-	-	-	-	-
Men-C-C	-	Men-C-C^{Table 1 Footnote F} According to P/T schedule			Men-C-C ^{Table 1 Footnote F} Generally at 12 months						-	-	-	-	-	-	-	-
Men-C-C or Men-C-ACYW	-	-	-	-	-	-	-	-	-	-	-	-	-	Men-C-C or Men-C-ACYW^{Table 1 Footnote G}	-	-	-	-
MMR and Var	-	-	-	-	MMR ^{Table 1 Footnote H} + Var ^{Table 1 Footnote I}		MMR^{Table 1 Footnote H} + Var ^{Table 1 Footnote I}						-	-	-	-	-	-
OR
MMRV	-	-	-	-	MMRV^{Table 1 Footnote J}		MMRV Generally at 4-6 years^{Table 1 Footnote J}						-	-	-	-	-	-
HB	HB 3 doses^{Table 1 Footnote K}					-	-	-	-	-	-	-	-	-	-	-	-	-
OR
HB	-	-	-	-	-	-	-	-	-	-	-	-	HB 2 or 3 doses^{Table 1 Footnote L}
HPV	-	-	-	-	-	-	-	-	-	-	-	-	HPV 1 dose^{Table 1 Footnote M}
Inf	-	-	-	Inf 1 or 2 doses Recommended annually^{Table 1 Footnote N}										Inf 1 dose Recommended annually^{Table 1 Footnote N}
RSV Ab	RSV mAbs 1 dose^{Table 1 Footnote O}			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Table 1 Footnote * For abbreviations and brand names of vaccines refer to Contents of immunizing agents authorized for use in Canada in Part 1. Table 1 Return to footnote * referrer Table 1 Footnote A Diphtheria toxoid- tetanus toxoid- acellular pertussis- inactivated polio- Haemophilus influenzae type b (DTaP-IPV-Hib). For infants and children beginning primary immunization at 7 months of age and older, the number of doses of Hib vaccine required varies by age. Table 1 Return to footnote A referrer Table 1 Footnote B Diphtheria toxoid- tetanus toxoid- acellular pertussis- hepatitis B- inactivated polio- Haemophilus influenzae type b (DTaP-HB-IPV-Hib). Alternative schedules may be used: DTaP-HB-IPV-Hib at 2, 4 and 12-23 months of age with DTaP-IPV-Hib vaccine at 6 months of age; or DTaP-HB-IPV -Hib at 2, 4 and 6 months of age with DTaP-IPV-Hib vaccine at 12-23 months of age. Table 1 Return to footnote B referrer Table 1 Footnote C Tetanus toxoid- reduced diphtheria toxoid- reduced acellular pertussis (Tdap): 10 years after last dose of DTaP- or Tdap-containing vaccine. Table 1 Return to footnote C referrer Table 1 Footnote D Rotavirus (Rot-5): Rotavirus pentavalent vaccine - 3 doses, 4 to 10 weeks apart; Rotavirus monovalent vaccine - 2 doses, at least 4 weeks apart. Give the first dose starting at 6 weeks and before 15 weeks of age. Administer all doses before 8 months of age. Table 1 Return to footnote D referrer Table 1 Footnote E Pneumococcal conjugate 15 or 20-valent (Pneu-C-15 or Pneu-C-20): infants without medical or environmental risk factors for invasive pneumococcal disease (IPD) beginning primary immunization at 2 to less than 7 months of age: 3 or 4 dose schedule. For a 3 dose schedule : 2, 4 months of age, followed by a booster dose at 12 to 15 months of age. For a 4 dose schedule: minimum of 8 weeks interval between doses beginning at 2 months of age, followed by a booster dose at 12 to 15 months of age. Infants without medical or environmental risk factors for IPD beginning primary immunization at 7 to less than 12 months of age: 2 doses, at least 8 weeks apart followed by a booster dose at 12 to 15 months of age, at least 8 weeks after the second dose. Children without medical or environmental risk factors for IPD who have received age-appropriate pneumococcal vaccination with Pneu-C-13 vaccine do not need an additional dose of Pneu-C-15 or Pneu-C-20. Table 1 Return to footnote E referrer Table 1 Footnote F Monovalent conjugate meningococcal(Men-C-C): children 12-48 months of age: 1 dose routinely provided at 12 months of age, regardless of any doses given during the first year of life. Immunization may be considered for unimmunized children 5-11 years of age. Table 1 Return to footnote F referrer Table 1 Footnote G Monovalent conjugate meningococcal (Men-C-C) or quadrivalent conjugate meningococcal (Men-C-ACYW): early adolescence (around 12 years of age) - 1 dose, even if conjugate meningococcal vaccine received at a younger age. Vaccine chosen depends on local epidemiology and programmatic considerations. Table 1 Return to footnote G referrer Table 1 Footnote H Measles-mumps-rubella (MMR): first dose at 12-15 months of age; second dose at 18 months of age or anytime thereafter, but should be given no later than around school entry. Table 1 Return to footnote H referrer Table 1 Footnote I Varicella (chickenpox) (Var): first dose at 12-15 months of age; second dose at 18 months of age or anytime thereafter, but should be given no later than around school entry. Table 1 Return to footnote I referrer Table 1 Footnote J Measles-mumps-rubella-varicella (MMRV): first dose at 12-15 months of age; second dose at 18 months of age or anytime thereafter, but should be given no later than around school entry. Table 1 Return to footnote J referrer Table 1 Footnote K Hepatitis B (HB): months 0, 1 and 6 (first dose = month 0) with at least 4 weeks between the first and second dose, at least 2 months between the second and third dose, and at least 4 months between the first and third dose. Alternatively, can be administered as DTaP-HB-IPV-Hib vaccine, with first dose at 2 months of age. Table 1 Return to footnote K referrer Table 1 Footnote L Hepatitis B (HB): 9-17 years of age - months 0, 1 and 6 (first dose = month 0) with at least 4 weeks between the first and second dose, at least 2 months between the second and third dose, and at least 4 months between the first and third dose. 11-15 years of age - 2 doses; schedule depends on the product used. Table 1 Return to footnote L referrer Table 1 Footnote M Human papillomavirus (HPV): Individuals 9 to 17 years of age, unless immunocompromised, should receive one dose of HPV nonavalent (9vHPV) vaccine. A 2-dose schedule may be considered on an individual basis for individuals 9 to 17 years of age in discussion with their health care provider. For a 2-dose schedule, doses should be administered at least 24 weeks apart - months 0 and 6 (first dose = month 0). Table 1 Return to footnote M referrer Table 1 Footnote N Influenza (Inf): recommended annually for anyone 6 months of age and older without contraindications. Children 6 months-less than 9 years of age, receiving influenza vaccine for the first time - 2 doses, at least 4 weeks apart. Children 6 months-8 years of age, previously immunized with influenza vaccine and children 9 years of age and older - 1 dose. Table 1 Return to footnote N referrer Table 1 Footnote O Respiratory syncytial virus monoclonal antibodies (RSV Ab): Nirsevimab is recommended for neonates and infants, entering or during their first RSV season. Ideally, RSV Ab are administered just before the RSV season begins (typically fall through spring) or within the first weeks of life for those born during the RSV season. Table 1 Return to footnote O referrer

Table 2: Recommended immunization schedule, children (less than 7 years of age), NOT previously immunized as infants

For children at-risk due to underlying medical conditions, refer to Table 4 for additional recommendations for immunization.
[ ] = dose(s) may not be required depending upon age of child or vaccine used or both (refer to the relevant vaccine-specific chapter in Part 4 and provincial/territorial schedule). mos = months.
Refer to Timing of vaccine administration and Vaccine administration practices in Part 1 regarding administration of multiple injections.
Refer to vaccine-specific chapters in Part 4 for additional information.

Table 2: Recommended immunization schedule, children (less than 7 years of age), not previously immunized as Infants
Vaccine^{Footnote *}	First visit	Time after first visit					6-12 mos after last dose
Vaccine^{Footnote *}	First visit	4 weeks	8 weeks	3 mos	4 mos	6 mos	6-12 mos after last dose
DTaP-IPV-Hib or DTaP-IPV	^{Footnote A}	-	^{Footnote A}	-	^{Footnote A}	-	^{Footnote A} ^{Footnote B}
DTaP-HB-IPV-Hib^{Footnote C}	^{Footnote D}	-	^{Footnote D}	-	^{Footnote D}	-	^{Footnote D}
Pneu-C-15 or 20	^{Footnote E}	-	^{Footnote E}	-	-	-	-
Men-C-C	^{Footnote F}	-	-	-	-	-	-
MMR	^{Footnote G}	^{Footnote G}	-	-	-	-	-
Var	^{Footnote H}	-	-	^{Footnote H}	-	-	-
OR
MMRV	^{Footnote I}	-	-	^{Footnote I}	-	-	-
HB	^{Footnote I}	^{Footnote I}	-	-	-	^{Footnote I}	-
Inf	^{Footnote K}	^{Footnote K}	-	-	-	-	-
Table 2 - Footnote * For abbreviations and brand names of vaccines refer to Contents of immunizing agents authorized for use in Canada in Part 1. Return to Table 2 footnote * referrer Table 2 - Footnote A *Diphtheria toxoid- tetanus toxoid- acellular pertussis- inactivated polio- Haemophilus influenzae* type b (DTaP-IPV-Hib) or diphtheria toxoid- tetanus toxoid- acellular pertussis- inactivated polio (DTaP-IPV): 4 doses of DTaP-IPV-containing vaccine. The number of doses of Hib-containing vaccine required varies by age at first dose. If first visit at 12 to 14 months of age: 1 dose of Hib-containing vaccine at first visit and booster dose at least 2 months after the previous dose. If first visit at 15 months-less than 60 months of age: 1 dose of Hib-containing vaccine. If first visit at 60 months of age or older, Hib-containing vaccine is not required. Return to first Table 2 footnote A referrer Table 2 - Footnote B Diphtheria toxoid- tetanus toxoid- acellular pertussis- inactivated polio (DTaP-IPV) or tetanus toxoid- reduced diphtheria toxoid- reduced acellular pertussis- inactivated polio (Tdap-IPV): if the fourth dose of DTaP-IPV vaccine was given before the fourth birthday, a booster dose of DTaP-IPV or Tdap-IPV vaccine should be provided at 4 to 6 years of age. Return to Table 2 footnote B referrer Table 2 - Footnote C Diphtheria toxoid- tetanus toxoid- acellular pertussis- hepatitis B- inactivated polio- Haemophilus influenzae type b (DTaP-HB-IPV-Hib): DTaP-HB-IPV-Hib vaccine is authorized for use for children 6 weeks to less than 24 months of age, but may be given to a child less than 7 years of age, if necessary. Refer to the Hepatitis B vaccines chapter in Part 4 for additional information. Return to first Table 2 footnote C referrer Table 2 - Footnote D Diphtheria toxoid- tetanus toxoid- acellular pertussis- hepatitis B- inactivated polio- Haemophilus influenzae type b (DTaP-HB-IPV-Hib): For children 6 months to less than 24 months of age: months 0, 2, 4, 10-21 (1st dose = month 0). In this age group, a three-dose schedule can also be used: months 0, 2, 4 or months 0, 2, 10-21. Return to Table 2 footnote D referrer Table 2 - Footnote E Pneumococcal conjugate 15 or 20-valent (Pneu-C-15 or Pneu-C-20): For children without medical or environmental IPD risk factors, 12 to less than 24 months of age - 2 doses, at least 8 weeks apart. 24 to less than 60 months of age - 1 dose. Return to first Table 2 footnote E referrer Table 2 - Footnote F Monovalent conjugate meningococcal (Men-C-C): 12 to 59 months of age - 1 dose; 5 to 11 years of age - consider 1 dose. Return to first Table 2 footnote F referrer Table 2 - Footnote G Measles-mumps-rubella (MMR): 2 doses, at least 4 weeks apart; second dose after 18 months of age, but should be given no later than around school entry. Return to first Table 2 footnote G referrer Table 2 - Footnote H Varicella (chickenpox) (Var): 2 doses, at least 3 months apart; second dose after 18 months of age, but should be given no later than around school entry. A minimum interval of 4 weeks between doses may be used if rapid, complete protection is required. Return to first Table 2 footnote H referrer Table 2 - Footnote I Measles-mumps-rubella-varicella (MMRV): 2 doses, at least 3 months apart; second dose after 18 months of age, but should be given no later than around school entry. A minimum interval of 4 weeks between doses may be used if rapid, complete protection is required. Return to first Table 2 footnote I referrer Table 2 - Footnote J Hepatitis B (HB): 3 doses - months 0, 1 and 6 (first dose = month 0) with at least 4 weeks between the first and second dose, 2 months between the second and third dose, and 4 months between the first and third dose. Return to first Table 2 footnote J referrer Table 2 - Footnote K Influenza** (Inf): 2 doses, at least 4 weeks apart. Return to first Table 2 footnote K referrer

Table 3: Recommended immunization schedule, children (7 to 17 years of age), NOT previously immunized

For children at-risk due to underlying medical conditions, refer to Table 4 for additional recommendations for immunization.
[ ] = dose(s) may not be required depending upon age of child or vaccine used or both (refer to the relevant vaccine-specific chapter in Part 4 and provincial/territorial schedule). mos = months. yrs = years.
Refer to Timing of vaccine administration and Vaccine administration practices in Part 1 regarding administration of multiple injections.
Refer to the vaccine-specific chapters in Part 4 for additional information.

Table 3: Recommended immunization schedule, children (7 to 17 years of age), not previously immunized
Vaccine^{Table 3 Footnote *}	First visit	Time after first visit				6-12 mos after last dose	10 yrs after last dose
Vaccine^{Table 3 Footnote *}	First visit	4 weeks	8 weeks	3 mos	6 mos	6-12 mos after last dose	10 yrs after last dose
Tdap-IPV Tdap	^{Table 3 Footnote A}	-	^{Table 3 Footnote A}		-	^{Table 3 Footnote A}	^{Table 3 Footnote B}
Men-C-C	^{Table 3 Footnote [C]} 7-11 years of age	-	-	-	-	-	-
OR
Men-C-C or Men-C-ACYW	^{Table 3 Footnote D} 12-17 years of age	-	-	-	-	-	-
MMR	^{Table 3 Footnote E}	^{Table 3 Footnote E}	-	-	-	-	-
Var	^{Table 3 Footnote F}	-	-	^{Table 3 Footnote F}	-	-	-
OR
MMRV	^{Table 3 Footnote G} 7-12 years of age	-	-	^{Table 3 Footnote G}	-	-	-
HB	^{Table 3 Footnote H}	^{Table 3 Footnote [H]}	-	-	^{Table 3 Footnote H}	-	-
HPV	^{Table 3 Footnote I} 9-17 years of age	-	-	-	-	-	-
Inf	^{Table 3 Footnote J} 7-8 years of age	^{Table 3 Footnote J}	-	-	-	-	-
OR
Inf	^{Table 3 Footnote J} 9-17 years of age	-	-	-	-	-	-
Table 3 - Footnote * For abbreviations and brand names of vaccines refer to Contents of immunizing agents authorized for use in Canada in Part 1. Return to Table 3 footnote * referrer Table 3 - Footnote A Tetanus toxoid- reduced diphtheria toxoid- reduced acellular pertussis- inactivated polio (Tdap-IPV): 2 doses, 8 weeks apart; third dose 6 to 12 months after second dose. Return to first Table 3 footnote A referrer Table 3 - Footnote B Tetanus toxoid- reduced diphtheria toxoid- reduced acellular pertussis (Tdap): 10 years after last dose of Tdap-IPV. Return to Table 3 footnote B referrer Table 3 - Footnote C Monovalent conjugate meningococcal (Men-C-C): 7 to 11 years of age - consider 1 dose. Return to Table 3 footnote C referrer Table 3 - Footnote D Monovalent conjugate meningococcal (Men-C-C) or quadrivalent conjugate meningococcal (Men-C-ACYW): 12 to 17 years of age - 1 dose, even if meningococcal conjugate vaccine received at a younger age. Vaccine chosen depends on local epidemiology and programmatic considerations. Return to Table 3 footnote D referrer Table 3 - Footnote E Measles-mumps-rubella (MMR): 2 doses, at least 4 weeks apart. Return to first Table 3 footnote E referrer Table 3 - Footnote F Varicella (chickenpox) (Var): 7 to 12 years of age - 2 doses, at least 3 months apart. 13 years of age and older - 2 doses, 6 weeks apart. A minimum interval of 4 weeks between doses may be used if rapid, complete protection is required. Return to first Table 3 footnote F referrer Table 3 - Footnote G Measles-mumps-rubella-varicella (MMRV): 7 to 12 years of age - 2 doses, at least 3 months apart. A minimum interval of 4 weeks between doses may be used if rapid, complete protection is required. Return to first Table 3 footnote G referrer Table 3 - Footnote H Hepatitis B (HB): 7 to 17 years of age - 3 doses, months 0, 1 and 6 (first dose = month 0) with at least 4 weeks between the first and second dose, 2 months between the second and third dose, and 4 months between the first and third dose. 11 to 15 years of age - two doses; schedule depends on the product used. Return to first Table 3 footnote H referrer Table 3 - Footnote I Human papillomavirus (HPV): Individuals 9 to 17 years of age, unless immunocompromised, should receive one dose of HPV nonavalent (HPV9) vaccine. A 2-dose schedule may be considered on an individual basis for individuals 9 to 17 years of age in discussion with their health care provider. For a 2-dose schedule, doses should be administered at least 24 weeks apart - months 0 and 6 (first dose = month 0). Return to first Table 3 footnote I referrer Table 3 - Footnote J Influenza: children less than 9 years of age - 2 doses, at least 4 weeks apart. Children 9 years of age and older - 1 dose. Return to first Table 3 footnote J referrer

Table 4: Additional recommended immunizations, children (birth to 17 years of age), considered at risk due to underlying medical conditions

[ ] = dose(s) may not be required depending upon age of child or vaccine used or both (refer to vaccine-specific chapter in Part 4 and provincial/territorial schedule). mos = months. yrs = years.
Refer to Immunization of travellers and Immunization of workers in Part 3 for additional information about vaccines recommended for travellers and workers.
Refer to Immunization of immunocompromised persons and Immunization of persons with chronic diseases in Part 3 for additional condition-specific recommendations.
Refer to Timing of vaccine administration and Vaccine administration practices in Part 1 regarding administration of multiple injections.
Refer to the vaccine-specific chapters in Part 4 for additional information

Table 4: Additional recommended immunizations, children (birth to 17 years of age), considered at risk due to underlying medical condition
Immunizing Agent^{Footnote *}	Age
Immunizing Agent^{Footnote *}	Birth	2 mos	6 mos	12 mos	15 mos	18 mos	23 mos	2 years	3 years	5-8 yrs	9-17 yrs
Hib	-	-	-	-	-	-	-	-	-	^{Footnote A} 1 dose
Pneu-C-20	-	3 doses^{Footnote B}		1 dose^{Footnote B}				1 dose^{Footnote B} If not previously received
Men-C-ACYW	-	^{Footnote C} 2, 3 or 4 doses + additional booster doses									-
4CMenB	-	^{Footnote D} 2, 3 or 4 doses + additional booster doses
OR
MenB-fHBP	-	-	-	-	-	-	-	-	-	-	^{Footnote D} 10-17 years of age 3 doses
HA	-	-	-	^{Footnote E} 2 doses
HB	^{Footnote F} 3 or 4 doses
Inf	-	-	^{Footnote G} 1 or 2 doses annually					^{Footnote G} 1 dose annually
RSV Ab	^{Footnote H} First RSV season 1 dose OR 4 to 5 doses			^{Footnote H} Second RSV season 1 dose OR 4 to 5 doses			-	-	-	-	-
Footnote * For abbreviations and brand names of vaccines refer to Contents of immunizing agents authorized for use in Canada in Part 1. Return to Table 4 footnote * referrer Table 4 - Footnote A Haemophilus influenzae type b (Hib): 5 years of age and older with increased risk of invasive Hib disease - 1 dose regardless of prior history of Hib vaccination and at least 1 year after any previous dose. Return to Table 4 footnote A referrer Table 4 - Footnote B Pneumococcal conjugate 20-valent (Pneu-C-20): infants at high risk of IPD due to a medical, environmental or living condition - a 4-dose schedule at 2, 4, and 6 months followed by a dose at 12 to 15 months of age. The minimum interval between doses is 8 weeks. Unimmunized infants presenting for vaccination at 7 to less than 12 months of age should receive 2 doses of Pneu-C-20 vaccine at least 8 weeks apart followed by a third dose at 12 to 15 months of age, at least 8 weeks after the second dose. Infants with an interrupted or incomplete schedule who are less than 12 months of age should complete their immunization schedule as if no interruption had occurred. If pneumococcal vaccine series started with Pneu-C-13 or Pneu-C-15, give Pneu-C-20 vaccine to complete series. Children two years of age and older who are at increased risk of IPD and have never received any pneumococcal vaccination, should receive 1 dose of Pneu-C-20. Return to Table 4 footnote B referrer Table 4 - Footnote C Quadrivalent conjugate meningococcal (Men-C-ACYW): infants and children at high risk of invasive meningococcal disease (IMD): 2 to 11 months of age - 2 or 3 doses of Men-C-ACYW-CRM vaccine, 8 weeks apart with another dose between 12 to 23 months of age and at least 8 weeks after the previous dose; 12 to 23 months of age - 2 doses of Men-C-ACYW-CRM vaccine, 8 weeks apart; 24 months of age and older - 2 doses of any Men-C-ACYW vaccine, 8 weeks apart. Give additional booster doses every 3 to 5 years if last vaccinated at 6 years of age and younger and every 5 years if last vaccinated at 7 years of age and older. Return to first Table 4 footnote C referrer Table 4 - Footnote D Serogroup B meningococcal (4CMenB OR MenB-fHBP): infants and children at high risk of IMD caused by serogroup B should be offered: 2 to 11 months of age - 2 or 3 doses of 4CMenB vaccine, 8 weeks apart with another dose between 12 to 23 months of age and at least 8 weeks after the previous dose; 1 to 9 years of age- 2 doses of 4CMenB vaccine, 8 weeks apart; 10 years of age and older - 2 doses of 4CMenB vaccine, at least 4 weeks apart OR 10 years of age and older - 3 doses of MenB-fHBP vaccine, given 4 weeks apart, with another dose at least 4 months after dose two and at least 6 months after dose one. For serogroup B meningococcal vaccines, the timing of booster doses is yet to be determined. Return to Table 4 footnote D referrer Table 4 - Footnote E Hepatitis A (HA): 6 months of age and older in high-risk groups: 2 doses, given 6 to 36 months apart (depending on product used). Return to Table 4 footnote E referrer Table 4 - Footnote F Hepatitis B (HB): 3 or 4 doses of higher dose of monovalent hepatitis B vaccine recommended for those with certain immunocompromising conditions, chronic renal failure and dialysis. Premature infants weighing less than 2,000 grams at birth born to HB infected mothers: 4 doses. Return to Table 4 footnote F referrer Table 4 - Footnote G Influenza (Inf): recommended annually for all individuals 6 months of age and older without contraindications, with focus on children at risk of influenza-related complications. Children 6 months-less than 9 years of age receiving influenza vaccine for the first time: 2 doses, at least 4 weeks apart. Children 6 months-8 years of age, previously immunized with influenza vaccine and children 9 years of age and older: 1 dose. Return to Table 4 footnote G referrer Table 4 - Footnote H Respiratory syncytial virus monoclonal antibodies (RSVAb): RSVAbs are recommended for infants and children at increased risk of severe RSV disease. Prior to the COVID-19 pandemic, the RSV season in most of Canada was typically November to April and RSVAb is optimally administered just before the start of the RSV season. Nirsevimab should be prioritized over palivizumab however, if nirsevimab is not available, palivizumab should be used. First RSV season: For infants entering or born during their first RSV season: (1) who are at increased risk of severe RSV disease, including premature infants; (2) whose transportation for severe RSV disease treatment is complex, and/or whose risk of severe RSV disease intersects with established social and structural health determinants such as those experienced by some Indigenous communities across First Nations, Métis and Inuit populations, 1 dose of nirsevimab is recommended OR 4 or 5 doses of palivizumab. The interval between the first and second doses of palivizumab is 21 to 28 days, and the interval between subsequent doses is 28 to 35 days. The first dose of palivizumab is given at the onset of the RSV season, as determined by local epidemiology. Second RSV season: For infants and children entering their second RSV season and are at ongoing increased risk of severe RSV disease, 1 dose of nirsevimab is recommended OR 4 or 5 doses of palivizumab. The interval between the first and second doses of palivizumab is 21 to 28 days, and the interval between subsequent doses is 28 to 35 days. The first dose of palivizumab is given at the onset of the RSV season, as determined by local epidemiology. Return to Table 4 footnote H referrer

Table 5: Recommended immunization schedule, adults (18 years of age and older), NOT previously immunized

For adults considered at-risk, refer to Table 7 for additional recommendations for immunization.
[ ] = dose(s) may not be required depending upon age of vaccinee or vaccine used or both (refer to vaccine-specific chapter in Part 4 and provincial/territorial schedule). mos = months.
Refer to Immunization of travellers and Immunization of workers in Part 3 for additional information about vaccines recommended for travellers and workers.
Refer to Timing of vaccine administration and Vaccine administration practices in Part 1 regarding administration of multiple injections.
Refer to vaccine-specific chapters in Part 4 for further information.

Table 5: Recommended immunization schedule, adults (18 years of age and older), not previously immunized
Vaccine^{Footnote *}	First visit	Time after First visit				6-12 mos after last dose	10 years after last dose
Vaccine^{Footnote *}	First visit	4 weeks	6 weeks	8 weeks	6 mos	6-12 mos after last dose	10 years after last dose
Tdap-IPV Tdap Td IPV	^{Footnote A}	-	-	^{Footnote A}	-	^{Footnote A}	^{Footnote B}
MMR	^{Footnote C}	-	-	-	-	-	-
Var	^{Footnote D} 18 to 49 years of age	-	^{Footnote D}	-	-	-	-
OR
RZV	^{Footnote E} 50 years of age and older	-	-	^{Footnote E}	-	-	-
Pneu-C-20	65 years of age and older ^{Footnote F}	-	-	-	-	-	-
Men-C-C or Men-C-ACYW	^{Footnote G} 18 to 24 years of age	-	-	-	-	-	-
HPV	^{Footnote H}					-	-
Inf	^{Footnote I} Annually
RSV	^{Footnote J} 75 years of age and older	-	-	-	-	-	-
Footnote * For abbreviations and brand names of vaccines refer to Contents of immunizing agents authorized for use in Canada in Part 1. Return to Table 5 footnote * referrer Table 5 - Footnote A Three doses of either tetanus toxoid- reduced diphtheria (Td, if not previously immunized with tetanus or diphtheria), or polio-containing vaccine if at increased risk of polio (Tdap-IPV, if not previously immunized with tetanus, diphtheria and polio, or IPV, if not previously immunized with polio) provided with an interval of 8 weeks between the first two doses followed by a third dose administered 6 to 12 months after the second dose. One dose of reduced acellular pertussis-containing vaccine should be provided to those who never previously received a pertussis-containing vaccine in adulthood. Adults who are unimmunized against polio but are not at increased risk and have had a primary series of tetanus and diphtheria containing vaccine, should receive IPV-containing vaccine as a part of their next tetanus and diphtheria booster. Return to Table 5 footnote A referrer Table 5 - Footnote B Tetanus toxoid- reduced diphtheria toxoid (Td): 10 years after last dose of Td-containing vaccine. Return to Table 5 footnote B referrer Table 5 - Footnote C Measles-mumps-rubella (MMR): adults born in or after 1970 - 1 dose, except - travellers, health care workers, students in post-secondary educational settings, and military personnel - 2 doses, at least 4 weeks apart. Adults born before 1970 can be presumed to have acquired natural immunity to measles and mumps and do not need MMR vaccination except - non-immune military personnel or health care workers (2 doses, at least 4 weeks apart), non-immune travellers (1 dose), non-immune students in post-secondary educational settings (consider 1 dose). Rubella-susceptible adults, regardless of age - 1 dose. Return to Table 5 footnote C referrer Table 5 - Footnote D Varicella (chickenpox) (Var): adults 18 to 49 years of age without contraindications who do not meet the definition for varicella immunity (refer to Susceptibility and immunity at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-24-varicella-chickenpox-vaccine.html#p4c23a5c) - 2 doses, 6 weeks apart. The minimum interval between doses is 4 weeks; adults 50 years of age and older are generally presumed to be immune. Return to first Table 5 footnote D referrer Table 5 - Footnote E Recombinant Zoster Vaccine (RZV): adults 50 years of age and older - 2 doses, 2 to 6 months apart; may be considered for immunocompromised adults 50 years of age and older based on a case-by-case assessment of benefits vs risks. Return to Table 5 footnote E referrer Table 5 - Footnote F Pneumococcal conjugate 20-valent (Pneu-C-20): adults 65 years of age and older - 1 dose; immunization with Pneu-C-15 followed by Pneu-P-23 may be offered as an alternative to Pneu-C-20. Return to Table 5 footnote F referrer Table 5 - Footnote G Monovalent conjugate meningococcal (Men-C-C) or quadrivalent conjugate meningococcal (Men-C-ACYW): adults less than 25 years of age - 1 dose (vaccine chosen depends on local epidemiology). Return to Table 5 footnote G referrer Table 5 - Footnote H Human papillomavirus (HPV): Individuals 18 to 20 years of age, unless immunocompromised, should receive one dose of HPV nonavalent (HPV9) vaccine. A 2-dose schedule may be considered on an individual basis for individuals 18 to 20 years of age in discussion with their health care provider. Individuals 21 to 26 years of age, unless immunocompromised, should receive two doses of 9vHPV vaccine. Individuals 27 years of age and older, unless immunocompromised, may receive a two-dose schedule of 9vHPV vaccine with shared decision making and discussion with a healthcare provider. For a 2-dose schedule, doses should be administered at least 24 weeks apart - months 0 and 6 (first dose = month 0). Return to Table 5 footnote H referrer Table 5 - Footnote I Influenza (Inf): 1 dose recommended for adults without contraindications, with focus on: adults at high risk of influenza-related complications (including pregnant women, adults 65 years of age and older); adults capable of transmitting influenza to individuals at high risk; adults who provide essential community services; and people in direct contact during culling operations with poultry infected with avian influenza. Return to Table 5 footnote I referrer Table 5 - Footnote J Respiratory syncytial virus (RSV): A single dose of RSV vaccine, optimally administered just before the start of the RSV season, is recommended for adults 75 years of age and older, particularly for older adults at increased risk of severe RSV disease and for adults 60 years of age and older who are residents of nursing homes and other chronic care facilities. RSV immunization may be considered as an individual decision for adults 50 to 74 years of age in consultation with their healthcare provider. A single dose of either RSVPreF3, RSVpreF or mRNA-1345 can be used in adults 60 to 74 years of age. A single dose of RSVPreF3 can be used in adults 50 to 74 years of age. A pregnant woman or pregnant person, at 32 to 36 wGA, in conversation with their pregnancy care provider, might consider immunization with RSVpreF vaccine in advance of, or during, the RSV season. Return to Table 5 footnote J referrer

Table 6: Recommended immunizations, adults (18 years of age and older), previously immunized

For adults considered at-risk, refer to Table 7 for additional recommendations for immunization.
[] = dose may not be required.
Refer to Immunization of travellers and Immunization of workers in Part 3 for additional information about vaccines recommended for travellers and workers.
Refer to Timing of vaccine administration and Vaccine administration practices in Part 1 regarding administration of multiple injections.
Refer to vaccine-specific chapters in Part 4 for additional information.

Table 6: Recommended immunizations, adults (18 years of age and older), previously immunized
Vaccine^{Footnote *}	Age
Vaccine^{Footnote *}	18-26 years	27-49 years	50-59 years	60 years	65 years and older
Td	^{Footnote A} 1 dose every 10 years
Tdap	^{Footnote B} 1 dose
Pneu-C-20	-	-	-	-	^{Footnote C} 1 dose
RZV	-	-	^{Footnote D} 2 doses
Inf	^{Footnote E} Annually
Footnote * For abbreviations and brand names of vaccines refer to Contents of immunizing agents authorized for use in Canada in Part 1. Return to Table 6 footnote * referrer Table 6 - Footnote A Tetanus toxoid- reduced diphtheria toxoid (Td): 1 booster dose every 10 years. Return to Table 6 footnote A referrer Table 6 - Footnote B Tetanus toxoid- reduced diphtheria toxoid- reduced acellular pertussis (Tdap): 1 dose in adulthood for pertussis protection regardless of interval since last dose of tetanus toxoid- and diphtheria toxoid-containing vaccine; 1 dose in every pregnancy, ideally between 27 and 32 weeks of gestation, for pertussis protection of infants. Refer to Pertussis vaccine in Part 4 for additional information. Return to Table 6 footnote B referrer Table 6 - Footnote C Pneumococcal conjugate 20-valent (Pneu-C-20): Regardless of Pneu-C-13 or Pneu-P-23 vaccination status, 1 dose of Pneu-C-20 is recommended for all adults 65 years of age and older - 1 dose at least 1 year from either the last Pneu-C-13 dose or the last Pneu-P-23 dose. Return to Table 6 footnote C referrer Table 6 - Footnote D Recombinant Zoster Vaccine (RZV): adults 50 years of age and older - 2 doses, 2 to 6 months apart and at least 1 year after LZV. Return to Table 6 footnote D referrer Table 6 - Footnote E Influenza (Inf): recommended for all adults without contraindications, with focus on adults at high risk of influenza-related complications (including pregnant women, adults 65 years of age and older); adults capable of transmitting influenza to individuals at high risk; adults who provide essential community services; and people in direct contact during culling operations with poultry infected with avian influenza. One dose annually. Return to Table 6 footnote E referrer

Table 7: Additional recommended immunizations, adults (18 years of age and older), considered at risk

Refer to Immunization of travellers and Immunization of workers in Part 3 for information about vaccines recommended for travellers and workers.
Refer to Immunization of immunocompromised persons and Immunization of persons with chronic diseases in Part 3 for additional condition-specific immunization recommendations.
Refer to Timing of vaccine administration and Vaccine administration practices in Part 1 regarding administration of multiple injections.
Refer to vaccine-specific chapters in Part 4 for additional information.

Table 7: Additional recommended immunizations, adults (18 years of age and older), considered at risk
Vaccine^{Footnote *}	Age
Vaccine^{Footnote *}	18 years of age and older
Hib	^{Footnote A} 1 dose
IPV	^{Footnote B} 1 booster dose
MMR	^{Footnote C} Second dose
Pneu-C-20	^{Footnote D} 1 dose
Men-C-ACYW	^{Footnote E} 2 doses + booster doses
4CMenB	^{Footnote F} 2 doses
OR
MenB-fHBP	^{Footnote F} 3 doses
HA	^{Footnote G} 2 doses
HB	^{Footnote H} 3 or 4 doses
OR
HAHB	^{Footnote I} 3 or 4 doses
Inf	^{Footnote J} Annually
SMV	^{Footnote K} 2 doses
Typh-I	^{Footnote L} 1 dose + booster doses if at ongoing risk
OR
Typh-O	^{Footnote L} 4 doses + booster doses if at ongoing risk
Rab	^{Footnote M} 3 doses + booster doses if required
Var	^{Footnote N} 2 doses
RSV	^{Footnote O} 1 dose
Footnote * List is not exhaustive of travel vaccines. For abbreviations and brand names of vaccines refer to Contents of immunizing agents authorized for use in Canada in Part 1. Return to Table 7 footnote * referrer Table 7 - Footnote A Haemophilus influenzae type b (Hib): adults with increased risk of invasive Hib disease - 1 dose regardless of prior history of Hib vaccination and at least 1 year after any previous dose. Return to Table 7 footnote A referrer Table 7 - Footnote B Inactivated polio (IPV): 1 booster dose for adults at increased risk of exposure to polio. Return to Table 7 footnote B referrer Table 7 - Footnote C Measles-mumps-rubella (MMR): adults born in or after 1970 - 1 dose, except - travellers, health care workers, students in post-secondary educational settings, and military personnel - 2 doses, at least 4 weeks apart. Adults born before 1970 can be assumed to have acquired natural immunity to measles and mumps and do not need MMR vaccination except - non-immune military personnel or health care workers (2 doses, at least 4 weeks apart), non-immune travellers (1 dose), non-immune students in post-secondary educational settings (consider 1 dose). Rubella-susceptible adults, regardless of age - 1 dose. Return to Table 7 footnote C referrer Table 7 - Footnote D Pneumococcal conjugate 20-valent (Pneu-C-20): all adults with medical or environmental conditions that result in an increased risk of IPD: Immunodeficiencies; immunocompromising therapy, HIV infection, hematopoietic stem cell transplant (recipient), malignant neoplasms, solid organ or islet transplant (recipient), chronic kidney or liver, disease, asplenia or splenic dysfunction, chronic cerebrospinal fluid leak, cochlear implants, and people who are experiencing homelessness, live in settings experiencing sustained high IPD rates, or who are in residential care, including long-term care homes; adults 50 years of age and older with chronic heart or lung disease, chronic neurologic conditions that impair clearance of oral secretions, diabetes mellitus, who smoke, with substance use disorders or with an alcohol use disorder, should receive Pneu-C-20; adults 18 to 49 years of age with chronic heart or lung disease, chronic neurologic conditions that impair clearance of oral secretions, diabetes mellitus, who smoke, with substance use disorders or with an alcohol use disorder, may be offered Pneu-C-15 or Pneu-C-20 at clinical discretion. - 1 dose of Pneu-C-20 vaccine is recommended, Pneu-C-15 followed by Pneu-P-23 may be offered as an alternative. Return to Table 7 footnote D referrer Table 7 - Footnote E Quadrivalent conjugate meningococcal (Men-C-ACYW): in previously unimmunized adults at high risk of invasive meningococcal disease (IMD) - 2 doses, 8 weeks apart. In previously immunized adults - booster dose every 3 to 5 years if last vaccinated at 6 years of age and younger and every 5 years for those last vaccinated at 7 years of age and older. Return to Table 7 footnote E referrer Table 7 - Footnote F Serogroup B meningococcal (4CMenB OR MenB-fHBP): previously unimmunized adults at high risk of IMD caused by serogroup B should be offered: 2 doses of 4CMenB vaccine, given at least 4 weeks apart OR 3 doses of MenB-fHBP vaccine, given 4 weeks apart, with another dose at least 4 months after dose two and at least 6 months after dose one. Serogroup B Meningococcal vaccines are not authorized for use in those 26 years of age however, based on limited evidence and expert opinion, their use is considered appropriate above these authorized ages. For serogroup B meningococcal vaccines, the timing of booster doses is yet to be determined. Return to Table 7 footnote F referrer Table 7 - Footnote G Hepatitis A (HA): adults in high risk groups - 2 doses, 6 to 36 months apart (depending on product used). Return to Table 7 footnote G referrer Table 7 - Footnote H Hepatitis B (HB): adults in high risk groups - 3 or 4 dose schedule (depending on product used). Higher dose of monovalent HB vaccine recommended for those with certain immunocompromising conditions, chronic renal failure and dialysis. Return to Table 7 footnote H referrer Table 7 - Footnote I Hepatitis A-hepatitis B (HAHB): adults without chronic renal failure and immunocompromising conditions: combined vaccine preferred if both hepatitis A and standard dosage hepatitis B vaccines are recommended - 3 or 4 dose schedule. Return to Table 7 footnote I referrer Table 7 - Footnote J Influenza (Inf): recommended for all adults, with focus on adults at high risk of influenza-related complications - 1 dose annually. Return to Table 7 footnote J referrer Table 7 - Footnote K Third-generation (SMV): adults at high risk of mpox (pre-exposure immunization) and adults who have had high-risk exposure(s): to a probable or confirmed case of mpox, or within a setting where transmission is happening (post-exposure immunization). Although there are limited data regarding SMV use among specific populations (e.g., immunocompromised due to disease or treatment; pregnancy or breastfeeding), these individuals are at higher risk of severe disease and should be offered SMV if vaccination is recommended based on high-risk criteria for pre- or post-exposure immunization. Pre-exposure immunization: It is recommended that adults at high risk of mpox should receive 2 doses of SMV administered at least 28 days (4 weeks) apart. Post-exposure immunization: A post-exposure dose of SMV should be offered as soon as possible, preferably within 4 days of last exposure. However, it can be considered up to 14 days following last exposure. Regardless of ongoing exposure status, a second dose of SMV should be offered at least 28 days following the first dose if mpox did not develop. Return to Table 7 footnote K referrer Table 7 - Footnote L Typhoid: adults with ongoing or intimate exposure to a chronic carrier of Salmonella typhi - 1 dose injectable typhoid (Typh-I) vaccine or 4 doses oral typhoid vaccine (Typh-O); re-immunization recommended if at continuing risk. Return to first Table 7 footnote L referrer Table 7 - Footnote M Rabies (HDCV or PCECV): adults at high risk of close contact with rabid animals - 3 doses for pre-exposure immunization. Periodic serologic testing and booster doses (if required) for those at continuing high risk. Return to Table 7 footnote M referrer Table 7 - Footnote N Varicella (chickenpox) (Var): adults 18 to less than 50 years of age without history of VZV infection (self-reported or diagnosed by a health care provider), documented evidence of immunization with 2 doses of a varicella-containing vaccine or laboratory evidence of immunity - 2 doses. Self-reported history or health care provider diagnosis is not considered a reliable correlate of immunity for pregnant women with significant exposure to varicella zoster virus, immunocompromised individuals and health care workers who are newly hired into the Canadian health care system. Return to Table 7 footnote N referrer Table 7 - Footnote O Respiratory syncytial virus (RSV): A single dose of RSV vaccine, optimally administered just before the start of the RSV season, is recommended for adults 75 years of age and older, particularly for older adults at increased risk of severe RSV disease, and for adults 60 years of age and older who are residents of nursing homes and other chronic care facilities. RSV immunization may be considered as an individual decision for adults 50 to 74 years of age in consultation with their healthcare provider. A single dose of either RSVPreF3, RSVpreF or mRNA-1345 can be used in adults 60 to 74 years of age. A single dose of RSVPreF3 can be used in adults 50 to 74 years of age. Return to Table 7 footnote O referrer

Page details

Date modified:: 2025-05-01

Language selection

Search